Plain-English translation of NCT06498622 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two medications — donafenib and envafolimab — can help prevent liver cancer from coming back after surgery. Some patients are at higher risk of recurrence even after successful surgery. This study wants to learn if giving these two medications together after surgery can improve outcomes and keep people cancer-free longer.
After surgery to remove liver cancer, the disease comes back in many patients, especially those at high risk. Right now, there is no standard medication doctors routinely give after surgery to prevent this. This trial is exploring whether this combination treatment can reduce the chance of cancer returning and help people live longer.
You likely qualify if…
You likely don't qualify if…
You would take donafenib as a daily oral tablet and receive envafolimab as an injection every three weeks. The treatment would continue for 6–12 months or up to 16 infusions, unless your cancer returns, you experience intolerable side effects, or you decide to stop. You would have regular follow-up appointments and imaging scans to monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China